Skip directly to content

TAG Comments Delivered at FDA Public Meeting on LPAD

August 9, 2019 – Lizzy Lovinger, Governmental Relations and Policy Officer, presented comments on behalf of TAG at the FDA Public Meeting on Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on July 12, 2019. LPAD is a proposed new pathway to drug approval, which would allow drugs to be approved for certain conditions affecting limited populations, after having been studied in smaller numbers of people than normally required. TAG expressed concern that if LPAD goes forward as written, it would enable pharmaceutical companies to rush drugs into the market without ensuring that these drugs are safe to use or more effective than existing interventions. All patients deserve treatment that has been rigorously tested to confirm benefits outweigh risks.

Read/Download the Full Comment

View the Meeting Agenda